Emerging nonsteroidal therapies, including CRF1 receptor antagonists, have the potential to decrease ACTH-driven adrenal androgen excess and its associated comorbidities during childhood even before clinical symptoms develop in patients with CAH (37-42). Here, POMC is linked to congenital adrenal hyperplasia.